Global Cancer Biological Therapy Market 2018 Size, Development Status, Type and Application, Segmentation, Forecast by 2023

WiseGuyReports.com adds “Cancer Biological Therapy Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023”reports to its database.

Pune, India - January 12, 2018 /MarketersMedia/ —

Cancer Biological Therapy Market:

Executive Summary

Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. There are various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as; cancer targeted therapies.

The global cancer biological therapy market is expected to reach USD 82,276.8 million by 2023 at a CAGR of 4.7% during the forecasted period.  

The global cancer biological therapy market is segmented on the basis of phases, types, end users and regions. On the basis of phases, the market is segmented into phase I, phase II and phase III. In stage I & II the real impact of these therapies is seen and giving a success rate of 35% in Phase 1 and 20% in Phase II. The success rate of phase I is 35%.

On the basis on types, the global cancer biological therapy market is segmented into monoclonal antibodies, cancer growth blockers, interferons, interleukins, gene therapy, targeted drug delivery, colony stimulating factor, cancer vaccines and others. Monoclonal antibodies accounted for the largest market share of the global cancer biological therapy market. Colony stimulating factor is the fastest growing market at a CAGR of 5.2% during the forecasted period.

On the basis on end users, hospitals & clinics dominates the global cancer biological therapy market. Registering USD 26,790.6 million in 2016 and expected to reach at USD 38,471.9 million by 2023 at the rate of 4.4 % from 2016-2023. 

On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific and the Middle East & Africa. North America has the dominating market for cancer biological therapy. The cancer biological therapy market for North America is estimated at USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Players

The leading market players in the global cancer biological therapy market include Merck Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Bristol-Myers Squibb, Celgene, ELI Lilly and Company, EnGeneIC, and Pfizer

Study objectives

To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global cancer biological therapy market
To provide insights about factors influencing and affecting the market growth
To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
To provide historical and forecast revenue of the market segments based on channels, applications, and regions for the global cancer biological therapy market.
To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
To provide economical factors that influences the global cancer biological therapy market
To provide detailed analysis of the value chain and supply chain of the global cancer biological therapy market

Target Audience

Pharmaceutical Companies
Pharmaceutical Suppliers
Cancer Research Organizations
Potential Investors
Key Executive (CEO and COO) and Strategy Growth Manager
Reaserch Companies

For further information on this report, visit - https://www.wiseguyreports.com/enquiry/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Findings

North America accounted for the largest market share in the global cancer biological therapy market, USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%
Colony stimulating factor is the fastest growing segment with a CAGR of and 5.2% in the global cancer biological therapy market, by types
Hospitals and clinics is contributing remarkable share in the market registering 47.8% in the global cancer biological therapy market, by end users in 2016

The reports also covers regional analysis

North America
o US

o Canada

Europe
o Germany

o France

o U.K.

o Italy

o Spain

o Rest of Europe

Asia Pacific
o Japan

o China

o India

o Republic of Korea

o Rest of Asia-Pacific

Middle East & Africa
o Middle East

o Africa

Continuous…

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1793685

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: Wise Guy Research Consultants Pvt Ltd
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349 (US); +44 208 133 9349 (UK)

Source URL: https://marketersmedia.com/global-cancer-biological-therapy-market-2018-size-development-status-type-and-application-segmentation-forecast-by-2023/286775

For more information, please visit https://www.wiseguyreports.com/reports/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Source: MarketersMedia

Release ID: 286775

More News From Daily World Web

Disney emphasizes China roots in Shanghai amid trade tension

Apr 26, 2018

SHANGHAI — Walt Disney Co. stressed its deep China connections as it opened an extension of Shanghai's $5.5 billion Disney Resort on Thursday amid escalating tensions over trade and technology between Beijing and Washington. Disney executives took pains to emphasize that beneath the surface, Shanghai's Disneyland is not purely American and has been a boon to the local economy, providing both jobs and high-quality entertainment. Disney took an unusually collaborative approach to its Shanghai theme park, which opened in 2016. It handed over a 57 percent ownership stake to its state-owned Chinese partner, the Shanghai Shendi Group. "We're excited about...

Chinese automaker plans electric car production in SAfrica

Apr 26, 2018

BEIJING — A state-owned Chinese automaker announced plans Wednesday to produce electric vehicles in South Africa, highlighting the growing role of the world's largest auto market in a technology seen as the global industry's future. BAIC Group's announcement at the Beijing auto show, the industry's biggest sales event of the year, came as Nissan unveiled its first electric car designed for China while General Motors displayed Buick SUV it says can go 600 kilometers (375 miles) on one charge. Chinese automaker Geely debuted a gasoline-electric hybrid developed with its Swedish sister company, Volvo Cars. Electrics are money-losers for most producers,...

Shanghai gets automated bank with VR, robots, face scanning

Apr 26, 2018

SHANGHAI — Missed paying dues on your Communist Party membership? There's a bank for that - and it's fully automated. A state-owned Chinese bank has opened an automated branch equipped with facial-scanning software, a virtual reality room, a hologram machine, talking robots and touchscreens for paying utility bills and Communist Party fees, among other functions. The branch opened last week in central Shanghai's Huangpu district and is being hyped as China's first "unmanned bank." Beijing-based China Construction Bank says the high-tech branch is meant to make banking more convenient, personalized, and efficient. It also reflects growing competition from cashless payment...

ZTE protests US penalty, says it is seeking solution

Apr 26, 2018

BEIJING — ZTE Corp., one of China's biggest tech companies, warned Friday a ban on access to U.S. technology threatens its survival and said the company is looking for a legal solution. State-owned ZTE "may enter a state of shock," which will hurt its employees and U.S. suppliers, its chairman said, according to Chinese news reports. A separate company statement said the ban "threatens ZTE's existence." The ban was imposed Monday in a case involving exports of telecoms equipment to Iran and North Korea. U.S. companies are barred from selling technology to ZTE for seven years. The penalty comes as...

As doors close in the US, China's Huawei shifts to Europe

Apr 26, 2018

SHENZHEN, China — As trade disputes simmer, Chinese telecommunications giant Huawei, the No. 3 smartphone brand, is shifting its growth efforts toward Europe and Asia in the face of mounting obstacles in the U.S. market. Shenzhen-based Huawei, the world's largest maker of telecoms equipment, has long coveted access to the U.S. but recently laid off key American employees at its Washington D.C. office. The U.S. has regularly stymied Huawei's efforts to enter the America, citing national security concerns. Huawei has failed to find a U.S. carrier to partner with for its smartphones, and the Federal Communications Commission on Tuesday approved...

About Us

Daily World Web took the initiative to utilize the development in cloud and AI technology to create a free, instantaneous and borderless flow of news, the way it should be.

Contact us: sales[at]dailyworldweb.com

Subscribe Now!